Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Human parvovirus 4 in the blood supply and transmission by pooled plasma-derived clotting factors: does it matter?

Literature DB >> 22780892

Human parvovirus 4 in the blood supply and transmission by pooled plasma-derived clotting factors: does it matter?

Eric Delwart.

Abstract

Entities: Chemical Disease Gene Species

Mesh：

Substances：

Year: 2012 PMID： 22780892 PMCID： PMC3666916 DOI： 10.1111/j.1537-2995.2012.03721.x

Source DB: PubMed Journal: Transfusion ISSN： 0041-1132 Impact factor: 3.157

× No keyword cloud information.

72 in total

1. Defining "adequate" pathogen reduction performance for transfused blood components.

Authors: Raymond P Goodrich; Brian Custer; Shawn Keil; Michael Busch
Journal: Transfusion Date: 2010-08 Impact factor: 3.157

2. Immunoglobulin G and M antibodies to human parvovirus 4 (PARV4) are frequently detected in patients with HIV-1 infection.

Authors: Shiu-Ju Yang; Chien-Ching Hung; Sui-Yuan Chang; Kuang-Lun Lee; Mao-Yuan Chen
Journal: J Clin Virol Date: 2011-02-24 Impact factor: 3.168

3. Virologic and clinical features of primary infection with human parvovirus 4 in subjects with hemophilia: frequent transmission by virally inactivated clotting factor concentrates.

Authors: Colin P Sharp; Alice Lail; Sharyne Donfield; Edward D Gomperts; Peter Simmonds
Journal: Transfusion Date: 2011-11-02 Impact factor: 3.157

Review 4. Human parvovirus B19: general considerations and impact on patients with sickle-cell disease and thalassemia and on blood transfusions.

Authors: Svetoslav N Slavov; Simone Kashima; Ana Cristina Silva Pinto; Dimas Tadeu Covas
Journal: FEMS Immunol Med Microbiol Date: 2011-06-15

5. Parvovirus 4 in French in-patients: a study of hemodialysis and lung transplant cohorts.

Authors: Mhammed Touinssi; Martine Reynaud-Gaubert; Carine Gomez; Pascal Thomas; Bertrand Dussol; Yvon Berland; Agnes Basire; Christophe Picard; Jean-François Cantaloube; Philippe de Micco; Philippe Biagini
Journal: J Med Virol Date: 2011-04 Impact factor: 2.327

6. Transfusion transmission of highly prevalent commensal human viruses.

Authors: Flavien Bernardin; Eva Operskalski; Mike Busch; Eric Delwart
Journal: Transfusion Date: 2010-11 Impact factor: 3.157

7. Human parvovirus PARV4 DNA in tissues from adult individuals: a comparison with human parvovirus B19 (B19V).

Authors: Fabiana Corcioli; Krystyna Zakrzewska; Rosa Fanci; Vincenzo De Giorgi; Massimo Innocenti; Matteo Rotellini; Simonetta Di Lollo; Alberta Azzi
Journal: Virol J Date: 2010-10-15 Impact factor: 4.099

8. High frequency, sustained T cell responses to PARV4 suggest viral persistence in vivo.

Authors: Ruth Simmons; Colin Sharp; Stuart Sims; Henrik Kloverpris; Philip Goulder; Peter Simmonds; Paul Bowness; Paul Klenerman
Journal: J Infect Dis Date: 2011-05-15 Impact factor: 5.226

9. Serodiagnosis of primary infections with human parvovirus 4, Finland.

Authors: Anne Lahtinen; Pia Kivelä; Lea Hedman; Arun Kumar; Anu Kantele; Maija Lappalainen; Kirsi Liitsola; Matti Ristola; Eric Delwart; Colin Sharp; Peter Simmonds; Maria Söderlund-Venermo; Klaus Hedman
Journal: Emerg Infect Dis Date: 2011-01 Impact factor: 6.883

10. Changing epidemiology of human parvovirus 4 infection in sub-Saharan Africa.

Authors: Colin P Sharp; Marion Vermeulen; Yacouba Nébié; Cyrille F Djoko; Matthew LeBreton; Ubald Tamoufe; Anne W Rimoin; Patrick K Kayembe; Jean K Carr; Annabelle Servant-Delmas; Syria Laperche; G L Abby Harrison; Oliver G Pybus; Eric Delwart; Nathan D Wolfe; Andrew Saville; Jean Jacques Lefrère; Peter Simmonds
Journal: Emerg Infect Dis Date: 2010-10 Impact factor: 6.883

5 in total

Human parvovirus 4 in the blood supply and transmission by pooled plasma-derived clotting factors: does it matter?

1. Defining "adequate" pathogen reduction performance for transfused blood components.

2. Immunoglobulin G and M antibodies to human parvovirus 4 (PARV4) are frequently detected in patients with HIV-1 infection.

3. Virologic and clinical features of primary infection with human parvovirus 4 in subjects with hemophilia: frequent transmission by virally inactivated clotting factor concentrates.

Review 4. Human parvovirus B19: general considerations and impact on patients with sickle-cell disease and thalassemia and on blood transfusions.

5. Parvovirus 4 in French in-patients: a study of hemodialysis and lung transplant cohorts.

6. Transfusion transmission of highly prevalent commensal human viruses.

7. Human parvovirus PARV4 DNA in tissues from adult individuals: a comparison with human parvovirus B19 (B19V).

8. High frequency, sustained T cell responses to PARV4 suggest viral persistence in vivo.

9. Serodiagnosis of primary infections with human parvovirus 4, Finland.

10. Changing epidemiology of human parvovirus 4 infection in sub-Saharan Africa.

Review 1. Molecular virology in transfusion medicine laboratory.

Review 2. Human parvovirus 4 'PARV4' remains elusive despite a decade of study.

3. The blood DNA virome in 8,000 humans.

4. Parvovirus 4 in Individuals with Severe Hemophilia A and Matched Control Group.

5. Identification of human parvovirus 4 genotypes 1 and 2 in Chinese source plasma pools.